A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to ...

PRNewswire London [UK] Munich [Germany] New Delhi [India] January 22 Datar Cancer Genetics DCG today announced the launch of ...

Laboratory technologies are transforming healthcare and proving vital in identifying and treating diseases <li /> Me ...

Companion Cancer Diagnostics Market The rising incidence of cancer worldwide is a primary driver of the Global Companion Cancer Diagnostics ...

Researchers at The University of Hong Kong (HKU) have made an exciting discovery about how human cells protect DNA during ...

The funding will be used to support the commercial rollout of Element’s benchtop instrument for next-generation sequencing (NGS), Aviti, which is a competitor to Illumina technology, like its ...

Like many cancer patients, Michael Wolff wanted answers. But, like many cancer patients in 2015, he wasn't getting them.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Immunoassay Kits & Reagents Dominate: These kits hold the largest market share (67.8% in 2022) and are predicted to grow ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI (TEM) announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx.